A phase Ib/II open label study of CDX-3379 a human monoclonal antibody targeting ERBB3 in combination with the MEK inhibitor trametinib in patients with advanced stage NRAS mutant and BRAF/NRAS wildtype (WT) melanoma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Melanoma
-
Age: Between 18 - 100 Years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1. Patients with a diagnosis of histologically confirmed advanced (defined as unresectable stage III or IV) melanoma with the NRAS Q61 mutation or BRAF/NRAS WT for which there is no remaining standard therapy with curative potential or patients are ineligible or unable to tolerate therapy with curative potential. 2. Patients must have archival tissue and at least one disease site amenable to biopsy
You may not be eligible for this study if the following are true:
-
1. Received CDX-3379 or other anti-ErbB3 targeted agents previously. 2. Received trametinib or other MEK inhibitor agents previously. 3. Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.